NovoCure Limited

NovoCure Limited

248.49
MXN
-73.90
(-22.92%)
-19.15EPS
Feb 25Next Earn

Important Dates

NovoCure Ltd.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of September 30, 2026, NovoCure Ltd. has 116.91M shares outstanding.

Shares Outstanding116.91M

Financial Position

As of September 30, 2026, NovoCure Ltd. maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Current Ratio2.49
Quick Ratio2.30
Debt / Equity66.04
Debt / EBITDA-2.15

Financial Efficiency

MXN

Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a negative return on equity (ROE) of -35.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.12, reflecting losses generated across the asset base. The company generates approximately 8.16M in revenue per employee across its workforce of 1,605.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.18 indicates how many times NovoCure Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-35.18
Return on Assets (ROA)-11.12
Revenue Per Employee8.16M
Employee Count1,605.00
Inventory Turnover4.18

Taxes

MXN

Over the twelve months ended September 30, 2026, NovoCure Ltd. recorded an income tax benefit of -159.16M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -2.36B and -2.20B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-159.16M

Stock Price Statistics

As of the close on November 6, 2026, NovoCure Ltd.'s stock has declined approximately 9.77% over the past 52 weeks.

52-Week Price Change-9.77%

Income Statement

MXN

Over the twelve months ended September 30, 2026, NovoCure Ltd. generated 13.10B in revenue and converted that into -2.20B in net income, yielding earnings per share of -19.15. EBITDA reached -1.94B, while operating income came in at -2.25B.

Revenue13.10B
Gross Profit10.09B
Operating Income-2.25B
Pretax Income-2.36B
Net Income-2.20B
EBITDA-1.94B
EBIT-2.25B
Earnings Per Share (EPS)-19.15

Balance Sheet

MXN

As of September 30, 2026, NovoCure Ltd. holds 8.37B in cash and equivalents against 4.18B in total debt, resulting in a net debt position of 1.80B. Total book value stands at 6.33B, with working capital of 7.27B providing operational flexibility.

Cash & Cash Equivalents8.37B
Total Debt4.18B
Net Debt1.80B
Equity (Book Value)6.33B
Book Value Per Share54.15
Working Capital7.27B

Cash Flow

MXN

NovoCure Ltd. produced -13.04M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -431.29M in capital expenditures, free cash flow totaled -444.33M - equivalent to -3.87 per share.

Operating Cash Flow-13.04M
Capital Expenditures-431.29M
Free Cash Flow-444.33M
FCF Per Share-3.87

Margins

Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a gross margin of 77.02, reflecting its pricing power and cost economics. The operating margin of -17.17 and net profit margin of -16.78 provide insight into operational efficiency.

Gross Margin77.02
Operating Margin-17.17
Pretax Margin-18.00
Profit Margin-16.78
EBITDA Margin-14.82